VolitionRx Statistics
Total Valuation
VolitionRx has a market cap or net worth of $24.80 million. The enterprise value is $33.40 million.
Important Dates
The last earnings date was Thursday, May 14, 2026, after market close.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
VolitionRx has 7.92 million shares outstanding. The number of shares has increased by 29.87% in one year.
| Current Share Class | 7.92M |
| Shares Outstanding | 7.92M |
| Shares Change (YoY) | +29.87% |
| Shares Change (QoQ) | +13.78% |
| Owned by Insiders (%) | 4.94% |
| Owned by Institutions (%) | 19.40% |
| Float | 6.88M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.06 |
| Forward PS | 12.76 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 13.54 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.33
| Current Ratio | 0.33 |
| Quick Ratio | 0.25 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.74 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -156.75% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 485.90% |
| Weighted Average Cost of Capital (WACC) | 12.19% |
| Revenue Per Employee | $32,881 |
| Profits Per Employee | -$327,974 |
| Employee Count | 75 |
| Asset Turnover | 0.28 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -69.40% in the last 52 weeks. The beta is 1.03, so VolitionRx's price volatility has been similar to the market average.
| Beta (5Y) | 1.03 |
| 52-Week Price Change | -69.40% |
| 50-Day Moving Average | 3.12 |
| 200-Day Moving Average | 6.86 |
| Relative Strength Index (RSI) | 60.19 |
| Average Volume (20 Days) | 297,632 |
Short Selling Information
The latest short interest is 269,068, so 3.40% of the outstanding shares have been sold short.
| Short Interest | 269,068 |
| Short Previous Month | 403,720 |
| Short % of Shares Out | 3.40% |
| Short % of Float | 3.91% |
| Short Ratio (days to cover) | 1.27 |
Income Statement
In the last 12 months, VolitionRx had revenue of $2.47 million and -$24.60 million in losses. Loss per share was -$4.21.
| Revenue | 2.47M |
| Gross Profit | 2.02M |
| Operating Income | -22.02M |
| Pretax Income | -24.73M |
| Net Income | -24.60M |
| EBITDA | -21.08M |
| EBIT | -22.02M |
| Loss Per Share | -$4.21 |
Full Income StatementBalance Sheet
The company has $3.10 million in cash and $11.70 million in debt, with a net cash position of -$8.60 million or -$1.09 per share.
| Cash & Cash Equivalents | 3.10M |
| Total Debt | 11.70M |
| Net Cash | -8.60M |
| Net Cash Per Share | -$1.09 |
| Equity (Book Value) | -33.36M |
| Book Value Per Share | -4.03 |
| Working Capital | -9.05M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$20.67 million and capital expenditures -$96,964, giving a free cash flow of -$20.76 million.
| Operating Cash Flow | -20.67M |
| Capital Expenditures | -96,964 |
| Depreciation & Amortization | 939,136 |
| Net Borrowing | 7.17M |
| Free Cash Flow | -20.76M |
| FCF Per Share | -$2.62 |
Full Cash Flow StatementMargins
| Gross Margin | 81.75% |
| Operating Margin | -892.75% |
| Pretax Margin | -1,002.82% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
VolitionRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -29.87% |
| Shareholder Yield | -29.87% |
| Earnings Yield | -99.18% |
| FCF Yield | -83.71% |
Analyst Forecast
The average price target for VolitionRx is $20.21, which is 545.69% higher than the current price. The consensus rating is "Buy".
| Price Target | $20.21 |
| Price Target Difference | 545.69% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 96.67% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 28, 2026. It was a reverse split with a ratio of 1:20.
| Last Split Date | Apr 28, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
